Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Neoadjuvant therapy is now standard in NSCLC – but can every patient complete the journey in the real world?
Clinical trials are promising. Real-world success, however, depends on:
- Careful patient selection.
- Rigorous performance status assessment.
- Early surgical planning.
- Strong multidisciplinary tumor board coordination.
In neoadjuvant strategies, the goal is not only response – it is safely delivering the patient to surgery. Timing matters. Logistics matter. Biology matters.”
Title: Neoadjuvant therapy for patients with nonsmall cell lung cancer: Not as easy in the real world
Auhtors: Giordano Fabricio Cittolin-Santos MD, PhD, Anjali Rohatgi MD, PhD
Read The Full Article
Other articles about Neoadjuvant Therapy on OncoDaily.